Retatrutide vs Tirzepatide
Retatrutide vs tirzepatide: the investigational triple agonist versus the FDA-approved dual agonist — mechanism, trial weight loss and legal status compared.
Retatrutide and tirzepatide are the two metabolic peptides everyone lines up against each other, and the core difference is one receptor plus one big status gap. Retatrutide is a triple agonist — it switches on GIP, GLP-1 and glucagon — and it is still investigational, available only inside clinical trials. Tirzepatide is the dual agonist (GIP + GLP-1) that’s already FDA-approved and sold by prescription as Mounjaro and Zepbound. Same drug family, one extra switch, and a world of difference in how you’d actually get each one.
On the numbers people care about, retatrutide’s TRIUMPH-1 phase 3 trial reported roughly 28% average weight loss at the top dose, compared with tirzepatide’s ~20% in phase 3 — but those come from separate studies over different lengths, not a head-to-head, so it’s a lead, not a settled ranking. That doesn’t crown a winner: tirzepatide is the proven, approved medicine you can take with a doctor today, with multiple completed phase 3 programs behind it, while retatrutide is the frontier still reading out. Both work best alongside diet and lifestyle, both should be used under medical supervision, and every regulatory line here is dated 2026 and worth re-checking. The by-goal picks below lay out the honest trade-offs.
Retatrutide vs Tirzepatide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Retatrutide | Tirzepatide |
|---|---|---|
| Drug class | A triple agonist — one molecule that switches on the GIP, GLP-1 and glucagon receptors. | A dual agonist — switches on the GIP and GLP-1 receptors, with no glucagon arm. |
| US regulatory status (2026) | Investigational — not FDA-approved; legitimately available only inside registered clinical trials. | FDA-approved and sold by prescription (Mounjaro, Zepbound). |
| Brand names | None — no brand or approved product; unapproved retatrutide is sold through gray-market and illicit compounded channels. | Mounjaro (type 2 diabetes) and Zepbound (weight management, plus obstructive sleep apnea). |
| Evidence base | Completed phase 2 RCTs; phase 3 is now reporting results, with other TRIUMPH and TRANSCEND trials and TRIUMPH-Outcomes ongoing. | Multiple completed phase 3 RCTs (SURMOUNT, SURPASS, SURMOUNT-OSA) that led to approval. |
| Weight change reported in trials | About 28% average body-weight reduction at the top 12 mg dose over 80 weeks (TRIUMPH-1 phase 3). | About 20% average body-weight reduction at the top 15 mg dose over 72 weeks (SURMOUNT-1). |
| Banned in sport | Effectively yes — unapproved, so it falls under WADA's S0 'non-approved substances', prohibited at all times. | No — GLP-1/GIP agonists are not on the WADA Prohibited List as of 2026 (confirm before competing). |
- Drug class: The glucagon receptor is the one extra switch retatrutide adds; it's thought to raise energy expenditure on top of appetite suppression.
- US regulatory status (2026): The biggest practical gap: tirzepatide is a real approved medicine, while retatrutide can only be obtained through a trial or the unregulated gray market.
- Evidence base: Both are graded on human-RCT evidence; tirzepatide has multiple completed phase 3 programs, while retatrutide's phase 3 program is now reading out.
- Weight change reported in trials: These are from separate trials over different durations, not a head-to-head — suggestive, not a settled ranking. Trial averages describe groups, not individuals.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
The largest weight loss reported so far
Leans toward Retatrutide
In TRIUMPH-1 phase 3, retatrutide's top dose cut body weight roughly 28% over 80 weeks, compared with the ~20% tirzepatide posted in phase 3 — but from separate studies, not a head-to-head, so treat it as a lead, not a verdict.
A proven, FDA-approved option you take with a doctor
Leans toward Tirzepatide
Tirzepatide is fully FDA-approved (Mounjaro, Zepbound) with completed phase 3 trials and a standardized prescription product; retatrutide is still investigational and only legitimately available inside a clinical trial.
The most complete safety and outcomes record today
Leans toward Tirzepatide
It has multiple completed phase 3 programs, including a cardiovascular-outcomes trial, while retatrutide's long-term and hard-outcome data (TRIUMPH-Outcomes) are still being gathered.
Watching the frontier of what these drugs can do
Leans toward Retatrutide
The added glucagon arm is the novel mechanism in the class, and retatrutide's remaining phase 3 readouts over the next few years are the ones to watch — the momentum is real, but it isn't approved yet.
References
- 1.Retatrutide TRIUMPH-1 phase 3 topline results
- 2.FDA concerns with unapproved retatrutide products
- 3.Tirzepatide — FDA prescribing information (DailyMed)
- 4.Drugs@FDA — approval status (tirzepatide approved; retatrutide not approved)
- 5.Retatrutide phase 2 obesity trial record (ClinicalTrials.gov, NCT04881760)
- 6.Retatrutide — indexed research (PubMed, National Library of Medicine)
- 7.Tirzepatide — indexed research (PubMed, National Library of Medicine)